Original Study

Excess Mortality Among Assisted Living Residents With Dementia During the COVID-19 Pandemic

Cassandra L. Hua PhD a,b,* Portia Y. Cornell PhD a,b, Sheryl Zimmerman PhD c, Paula Carder PhD d, Kali S. Thomas PhD a,b

a Department of Veterans Affairs Medical Center, Providence, RI, USA
b School of Public Health, Brown University, Providence, RI, USA
c Cecil G. Sheps Center for Health Services Research and the School of Social Work and Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
d Institute on Aging, Portland State University, Portland, Oregon, USA

Keywords:
SARS-CoV-2
long-term care
deaths
memory care

Abstract

Objective: To evaluate whether assisted living (AL) residents with Alzheimer’s disease and related dementias (ADRD) experienced a greater rate of excess all-cause mortality during the first several months of the COVID-19 pandemic compared to residents without ADRD, and to compare excess all-cause mortality rates in memory care vs general AL among residents with ADRD.

Design: Retrospective cohort study.

Setting and Participants: Two cohorts of AL residents enrolled in Medicare Fee-For-Service who resided in 9-digit ZIP codes corresponding to US AL communities of ≥25 beds during calendar year 2019 or 2020.

Method: By linking Medicare claims and Vital Statistics data, we examined the weekly excess all-cause mortality rate, comparing the rate from March 12, 2020, to December 31, 2020, to the rate from January 1, 2019, to March 11, 2020. We adjusted for demographics, chronic conditions, AL community size, and county fixed effects.

Results: Of the 286,350 residents in 2019 and the 273,601 in 2020 identified in these cohorts, approximately 31% had a diagnosis of ADRD. Among all AL residents, the excess weekly mortality rate in 2020 was 49.1 per 100,000 overall during the pandemic. Compared to residents without ADRD, residents with ADRD experienced 33.4 more excess deaths per 100,000 during the pandemic. Among residents with ADRD, those who resided in memory care communities did not experience a statistically significant different mortality rate than residents who lived in general AL.

Conclusions and Implications: AL residents with ADRD were more vulnerable to mortality during COVID-19 than residents without ADRD, a finding similar to those reported in other settings such as nursing homes. Additionally, the study provides important new information that residents with ADRD in memory care communities may not have been at differential risk of COVID-19 mortality when compared to residents with ADRD in general AL, despite prior research suggesting they have more advanced dementia.

Published by Elsevier Inc. on behalf of AMDA – The Society for Post-Acute and Long-Term Care Medicine.

The authors declare no conflicts of interest.

This study was supported by the National Institute on Aging (grant R01AG057746; Kali S. Thomas, principal investigator). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the National Institutes of Health, the Department of Veterans Affairs, or the US government.

* Address correspondence to Cassandra L. Hua, PhD, Center for Innovation in Long-Term Services & Supports, Providence VA Medical Center, 830 Chalkstone Avenue, Providence, RI 02908, USA. E-mail address: cassandra_hua@brown.edu (C.L. Hua).

https://doi.org/10.1016/j.jamda.2022.07.023
1525-8610/Published by Elsevier Inc. on behalf of AMDA – The Society for Post-Acute and Long-Term Care Medicine.

Older adults diagnosed with Alzheimer’s disease and related dementias (ADRD) have a higher risk of mortality from COVID-19 than older adults without ADRD. Long-term care residents with ADRD may be at particular risk of mortality during the COVID-19 pandemic when compared to residents without ADRD even after accounting for their age and comorbidities because they reside in a congregate setting and are less able to adhere to preventive practices such as use of masks and social distancing. Additionally, residents with ADRD require hands-on assistance from staff, potentially increasing their exposure to the virus.
Much of the literature on COVID-19 in long-term care has focused on nursing homes; much less is known about the experiences of assisted living residents.\textsuperscript{5-7} Assisted living (AL) communities warrant focused attention because of the size and vulnerability of the population: more than 63% of the over 800,000 individuals who live in AL have trouble getting out of bed and 48% have trouble dressing.\textsuperscript{1} Additionally, AL communities have variable infection control policies across states and a limited presence of licensed nursing staff.\textsuperscript{9,10} AL communities provide assistance with daily activities, at least 2 meals a day, and supervision for older adults who have some personal care needs but do not need daily nursing care.\textsuperscript{12} AL residents experienced increased rates of mortality during the COVID-19 pandemic compared to their rates of mortality prior to the pandemic.\textsuperscript{1} However, to our knowledge, it is not known whether the rate of all-cause mortality during the COVID-19 pandemic was different for residents of AL communities with ADRD than for residents without ADRD.

Additionally, no studies of which we are aware have examined rates of all-cause mortality during the COVID-19 pandemic comparing memory care communities to general AL. Although regulations for memory care vary by state, most states require that administrators and direct care staff receive dementia-specific training and that buildings contain features such as locked doors to prevent egress.\textsuperscript{11,12} Providers in memory-care AL communities may be better able to attend to the needs of residents with dementia than providers in general AL, helping to prevent the spread of infection to other residents. However, there is controversy as to whether memory care communities provide better care overall,\textsuperscript{10} which is important to understand given they cost 29% more on average than general AL.\textsuperscript{13} In fact, there is reason to hypothesize that outcomes in memory care are worse than those in general AL given that these residents tend to have more advanced dementia.\textsuperscript{14}

### Objectives

This study compared the weekly rate of excess all-cause mortality during the first several months of the COVID-19 pandemic among a US cohort of AL residents with ADRD to residents without ADRD. It also explored whether the weekly rate of excess all-cause mortality among residents with ADRD varied by whether the residents with ADRD lived in memory care AL or in general AL.

### Methods

#### Data

Information on AL communities came from a 2019 national directory we compiled from websites of state licensing agencies. Vital Statistics data were used to capture the date of death. The Medicare Beneficiary Summary file was used to obtain the demographic characteristics of the AL residents; the Chronic Conditions Data Warehouse subsection was used to identify residents with an ADRD diagnosis. Using Medicare enrollment data, we implemented a previously published methodology using 9-digit ZIP codes to create a finder file that identified residents in AL communities from the contiguous United States that had at least 25 beds.\textsuperscript{15}

#### Participants

Residents were included in the sample if they lived in AL on January 1 of either 2019 or 2020; their mortality was tracked for the entire year. We excluded Minnesota and Connecticut because those states license AL agencies rather than physical locations. We excluded residents with Medicare Advantage enrollment or without Medicare enrollment during the prior years (2018 and 2019) because the diagnosis data were incomplete for these residents. A subanalysis cohort was created to examine whether residing in memory care was associated with all-cause mortality during the first year of the COVID-19 pandemic among AL residents with dementia. Consistent with previous literature, we define a memory care community as an AL community with a state license, certification, or designation to provide care for residents with ADRD.\textsuperscript{11} For this analysis, we excluded AL residents who did not reside in the 30 states for which we had information on memory care licensure (see Supplementary Table 1). We also excluded AL residents who did not have ADRD. For a figure depicting our sample selection process, see Supplementary Figures 1 and 2.

### Measures

Our outcome was the weekly rate of mortality per 100,000 AL residents per week. We identified whether an individual had ADRD by the Chronic Conditions Data Warehouse flag. We used our directory of licensed AL communities to identify communities that had a license, certification, or designation to provide care for residents with ADRD. For our adjusted analysis, we included demographic characteristics from the Medicare Beneficiary Summary File as covariates; these included age (<65, 65-74, 75-84, 85-94, >95), sex, race or ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, and other), and dual enrollment in Medicaid. We also included chronic conditions associated with COVID-19 mortality\textsuperscript{16} [ie, asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, heart conditions (acute myocardial infarction, atrial fibrillation, congestive heart failure, or ischemic heart disease), hypertension, obesity, stroke, and number of chronic conditions {<2, 2-3, 4-5, >5} of those listed]. In addition, we incorporated a measure of AL bed size derived from our national directory.

### Statistical Methods

We did not expect mortality in 2020 to differ from 2019 prior to March 12, before many outbreaks were reported in the United States. Therefore, we confirmed this by plotting weekly rates of mortality, comparing the entire year of 2020 to the entire year of 2019. We estimated a linear probability model of the probability of death of individual \(i\) in week \(w\) and year \(y\) to examine weekly fluctuations in mortality comparing 2020 to 2019 using the following equation:

\[
M_{ipy} = a + \alpha \times \text{Week}_{iy} + \epsilon_{ipy} \quad \text{(Model 1)}
\]

The outcome \(M_{ipy}\) is the number of deaths per 100,000 AL residents per week. The vector \(a\) represents the differences in all-cause mortality for 2020 vs 2019 for each week \(w\) (1-52).

We then created an indicator for weeks that occurred on or after March 12 (March 12–December 31), the day before COVID-19 was declared a national emergency in the United States,\textsuperscript{1} and interacted it with our year variable (model 2):

\[
M_{ipy} = (\text{Year}_{2020y} \times \text{Pandemic}_p) + \epsilon_{ipy} \quad \text{(Model 2)}
\]

We used this interaction as a way to measure excess all-cause mortality related to COVID-19.

We stratified model 1 by diagnosis of ADRD to visualize how the weekly unadjusted rates of excess mortality differed for residents with and without ADRD for the entire year of 2020. We then used the pandemic period and year interaction model (model 2) to examine excess mortality during the pandemic comparing residents with ADRD to residents without ADRD. We calculated unadjusted models and models adjusting for age, sex, race, dual enrollment in Medicaid, and chronic conditions previously described. Given that bed size and local COVID-19 prevalence are the strongest predictors of COVID-19...
mortality in nursing homes,\textsuperscript{18} we controlled for AL bed size and county fixed effects.

The next analysis estimated similar sets of models among a sub-group of residents with ADRD. We included data only from residents in the 30 states where information was available regarding whether each community was licensed, certified, or designated to provide memory care. We adjusted for the same covariates as the first set of models; instead of an indicator for ADRD, we included an indicator for memory care. We adjusted for the same covariates as the previous analysis. The characteristics of residents with ADRD in memory care communities compared to those in general AL during both years are shown in Table 2. In both tables, we observed consistency in the characteristics of AL resident populations between the 2 years. For example, in both years, approximately 6% of AL residents with ADRD had 6 or more chronic conditions compared with 3% of AL residents without ADRD. During both years, 61%-62% of AL residents with ADRD who lived in memory care AL communities were aged ≥85 years.

**Main Results**

The average weekly all-cause mortality rate among AL residents in 2019 was 217.6 per 100,000 AL residents. Unadjusted excess weekly mortality in 2020 during the pandemic (after March 12) was 47.9 per 100,000 AL residents; adjusted weekly excess mortality was 49.1 per 100,000 (Table 3).

Figure 1 displays the unadjusted change in the rate of all-cause mortality each week per 100,000 AL residents in 2020 vs 2019, comparing AL residents with ADRD to residents without ADRD. The figure shows that residents with ADRD experienced higher excess mortality throughout the time period studied; these differences were greatest in April and December. As shown in Table 3, unadjusted rates of weekly excess all-cause mortality were 34.3 deaths per 100,000 higher among residents with ADRD compared to residents without

### Results

**Descriptive Data**

We identified 286,350 individuals living in a larger (≥25-bed) AL community on January 1, 2019, and 273,601 individuals on January 1, 2020; approximately 31% of residents in both years had an ADRD diagnosis. The characteristics of residents of AL residents with ADRD compared to residents without ADRD in both years are shown in Table 1. For our subanalysis, we identified 65,469 Medicare beneficiaries on January 1, 2019, and 61,964 individuals on January 1, 2020, residing in the 30 states. This subsample consisted of the 34% of residents in memory care licensed AL communities who had ADRD (reflecting the fact that some memory care licensed communities also provided care to residents who did not have ADRD). The characteristics of residents with ADRD in memory care communities compared to those in general AL during both years are shown in Table 2. In both tables, we observed consistency in the characteristics of AL resident populations between the 2 years. For example, in both years, approximately 6% of AL residents with ADRD had 6 or more chronic conditions compared with 3% of AL residents without ADRD. During both years, 61%-62% of AL residents with ADRD who lived in memory care AL communities were aged ≥85 years.

#### Table 1

**Characteristics of Assisted Living Residents With Alzheimer’s Disease and Related Dementias (ADRD) Compared to Residents Without ADRD, by Year**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>2019 (n = 88,520)</th>
<th>2020 (n = 83,824)</th>
<th>2019 (n = 197,830)</th>
<th>2020 (n = 189,777)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 y</td>
<td>3.6</td>
<td>3.4</td>
<td>8.8</td>
<td>8.6</td>
</tr>
<tr>
<td>65-74 y</td>
<td>9.9</td>
<td>10.1</td>
<td>20.9</td>
<td>21.4</td>
</tr>
<tr>
<td>75-84 y</td>
<td>25.8</td>
<td>26.3</td>
<td>27.5</td>
<td>27.9</td>
</tr>
<tr>
<td>85-94 y</td>
<td>48.9</td>
<td>47.9</td>
<td>35.9</td>
<td>35.0</td>
</tr>
<tr>
<td>≥95 y</td>
<td>11.8</td>
<td>12.3</td>
<td>7.0</td>
<td>7.1</td>
</tr>
<tr>
<td>Sex, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>31.0</td>
<td>31.2</td>
<td>35.9</td>
<td>36.2</td>
</tr>
<tr>
<td>Female</td>
<td>69.0</td>
<td>68.8</td>
<td>64.1</td>
<td>63.8</td>
</tr>
<tr>
<td>Race, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>91.6</td>
<td>91.4</td>
<td>91.1</td>
<td>90.9</td>
</tr>
<tr>
<td>Black</td>
<td>4.1</td>
<td>4.2</td>
<td>3.7</td>
<td>37</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.2</td>
<td>2.3</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Other</td>
<td>2.0</td>
<td>2.2</td>
<td>3.2</td>
<td>3.4</td>
</tr>
<tr>
<td>Dually enrolled in Medicare and Medicaid, %</td>
<td>20.5</td>
<td>20.5</td>
<td>16.2</td>
<td>16.0</td>
</tr>
<tr>
<td>Chronic conditions, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>6.3</td>
<td>6.5</td>
<td>5.7</td>
<td>5.7</td>
</tr>
<tr>
<td>Cancer</td>
<td>10.8</td>
<td>10.9</td>
<td>10.4</td>
<td>10.5</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>43.1</td>
<td>44.5</td>
<td>28.8</td>
<td>29.9</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>21.4</td>
<td>21.0</td>
<td>13.9</td>
<td>13.8</td>
</tr>
<tr>
<td>Diabetes</td>
<td>31.3</td>
<td>32.0</td>
<td>25.4</td>
<td>25.5</td>
</tr>
<tr>
<td>Heart disease</td>
<td>60.6</td>
<td>60.6</td>
<td>43.2</td>
<td>43.2</td>
</tr>
<tr>
<td>Hypertension</td>
<td>81.8</td>
<td>81.5</td>
<td>67.2</td>
<td>67.2</td>
</tr>
<tr>
<td>Obesity</td>
<td>14.5</td>
<td>15.1</td>
<td>16.7</td>
<td>17.4</td>
</tr>
<tr>
<td>Stroke</td>
<td>10.3</td>
<td>10.1</td>
<td>5.0</td>
<td>5.0</td>
</tr>
<tr>
<td>≤2 chronic conditions\textsuperscript{a}</td>
<td>23.2</td>
<td>22.8</td>
<td>39.0</td>
<td>38.5</td>
</tr>
<tr>
<td>2-3 chronic conditions\textsuperscript{a}</td>
<td>44.3</td>
<td>44.0</td>
<td>39.5</td>
<td>39.5</td>
</tr>
<tr>
<td>≥4-5 chronic conditions\textsuperscript{a}</td>
<td>26.7</td>
<td>27.3</td>
<td>18.3</td>
<td>18.7</td>
</tr>
<tr>
<td>≥6 chronic conditions\textsuperscript{a}</td>
<td>5.8</td>
<td>6.0</td>
<td>3.3</td>
<td>3.4</td>
</tr>
<tr>
<td>No. of chronic conditions, mean (SD)\textsuperscript{a,b}</td>
<td>2.8 (1.6)</td>
<td>2.8 (1.6)</td>
<td>2.2 (1.7)</td>
<td>2.2 (1.7)</td>
</tr>
</tbody>
</table>

Residents were enrolled in Medicare Fee-for-Service during the entire year prior and lived in assisted living on December 31, 2018, or December 31, 2019. Data were obtained from the 2018 and 2019 Medicare Master Beneficiary Summary file and chronic conditions files.

\textsuperscript{a}As of December 31, the year prior.

\textsuperscript{b}Of the conditions listed above.
Adjusted rates of excess weekly all-cause mortality were 33.4 excess deaths per week per 100,000 AL residents \((P < .001)\) among residents with ADRD.

Figure 2 shows the unadjusted excess mortality rate each week comparing residents in memory care AL communities to general AL communities. Residents in memory care had slightly lower excess mortality rates in April and May compared with the rest of the year, but higher excess mortality in other months such as June and July. CIs overlapped throughout the study period.

Table 3 displays the unadjusted and adjusted rates of excess all-cause mortality during the COVID-19 pandemic. On average, residents with ADRD who resided in memory care communities experienced 3.1 per 100,000 fewer excess deaths than residents with ADRD who did not reside in memory care communities during the 2020 pandemic period. However, this difference was not statistically significant \((P = .761)\). Adjusted rates were also not statistically significant \((5.0\text{ per }100,000\text{ fewer excess deaths}; P = .625)\).

**Discussion**

Consistent with pandemic mortality in nursing homes and in the community, AL residents with ADRD experienced substantially higher excess mortality from COVID-19 than those without ADRD.

---

**Table 2**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>2019 Memory Care Community Residents (n = 24,152)</th>
<th>2019 General Assisted Living Residents (n = 41,317)</th>
<th>2020 Memory Care Community Residents (n = 23,229)</th>
<th>2020 General Assisted Living Residents (n = 38,735)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 y</td>
<td>2.8</td>
<td>4.8</td>
<td>2.8</td>
<td>4.5</td>
</tr>
<tr>
<td>65-74 y</td>
<td>8.6</td>
<td>11.3</td>
<td>9.0</td>
<td>11.6</td>
</tr>
<tr>
<td>75-84 y</td>
<td>27.0</td>
<td>25.1</td>
<td>26.8</td>
<td>25.8</td>
</tr>
<tr>
<td>85 -94 y</td>
<td>50.4</td>
<td>47.2</td>
<td>49.5</td>
<td>46.1</td>
</tr>
<tr>
<td>95 y</td>
<td>11.2</td>
<td>11.6</td>
<td>12.0</td>
<td>12.0</td>
</tr>
<tr>
<td>Sex, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>30.0</td>
<td>31.7</td>
<td>30.7</td>
<td>31.7</td>
</tr>
<tr>
<td>Female</td>
<td>70.0</td>
<td>68.3</td>
<td>69.3</td>
<td>68.3</td>
</tr>
<tr>
<td>Race, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>93.1</td>
<td>91.1</td>
<td>93.1</td>
<td>90.7</td>
</tr>
<tr>
<td>Black</td>
<td>4.1</td>
<td>4.9</td>
<td>4.0</td>
<td>5.1</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1.5</td>
<td>2.4</td>
<td>1.6</td>
<td>2.5</td>
</tr>
<tr>
<td>Other</td>
<td>1.3</td>
<td>1.6</td>
<td>1.4</td>
<td>1.8</td>
</tr>
<tr>
<td>Dually enrolled in Medicare and Medicaid, %</td>
<td>16.9</td>
<td>26.3</td>
<td>17.0</td>
<td>26.6</td>
</tr>
<tr>
<td>Chronic conditions (%)^1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>5.8</td>
<td>6.4</td>
<td>6.2</td>
<td>6.6</td>
</tr>
<tr>
<td>Cancer</td>
<td>10.8</td>
<td>10.8</td>
<td>10.8</td>
<td>10.8</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>43.4</td>
<td>43.1</td>
<td>44.6</td>
<td>44.4</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>20.8</td>
<td>22.6</td>
<td>20.3</td>
<td>22.4</td>
</tr>
<tr>
<td>Diabetes</td>
<td>29.8</td>
<td>33.7</td>
<td>31.0</td>
<td>34.6</td>
</tr>
<tr>
<td>Heart disease</td>
<td>60.1</td>
<td>61.4</td>
<td>60.8</td>
<td>61.0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>82.4</td>
<td>82.2</td>
<td>82.3</td>
<td>82.1</td>
</tr>
<tr>
<td>Stroke</td>
<td>10.8</td>
<td>10.4</td>
<td>10.5</td>
<td>10.2</td>
</tr>
<tr>
<td>Obesity</td>
<td>13.8</td>
<td>15.8</td>
<td>14.3</td>
<td>16.5</td>
</tr>
<tr>
<td>&lt;2 chronic conditions^1</td>
<td>23.3</td>
<td>22.3</td>
<td>22.6</td>
<td>21.8</td>
</tr>
<tr>
<td>2-3 chronic conditions^1</td>
<td>45.3</td>
<td>43.5</td>
<td>44.8</td>
<td>43.3</td>
</tr>
<tr>
<td>4-5 chronic conditions^1</td>
<td>25.9</td>
<td>27.8</td>
<td>26.9</td>
<td>28.3</td>
</tr>
<tr>
<td>≥6 chronic conditions^1</td>
<td>5.5</td>
<td>6.4</td>
<td>5.8</td>
<td>6.6</td>
</tr>
<tr>
<td>No. of chronic conditions, mean (SD)^1</td>
<td>2.8 (1.6)</td>
<td>2.9 (1.7)</td>
<td>2.8 (1.6)</td>
<td>2.9 (1.7)</td>
</tr>
</tbody>
</table>

---

**Table 3**

<table>
<thead>
<tr>
<th>Excess Mortality for 2020 vs 2019, (\beta) (95% CI)</th>
<th>(P) Value</th>
<th>Excess Mortality ADRD vs Non-ADRD, (\beta) (95% CI)</th>
<th>(P) Value</th>
<th>Excess Mortality in Memory Care Communities vs General AL Among Residents With ADRD, (\beta) (95% CI)</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted rates of excess all-cause mortality for the pandemic period (3/12/2020-12/31/2020)</td>
<td>47.9 (44.2, 51.7)</td>
<td>&lt;.001</td>
<td>34.3 (26.8, 41.8)</td>
<td>&lt;.001</td>
<td>-3.1 (-2.3, 16.8)</td>
</tr>
<tr>
<td>Adjusted rates of excess all-cause mortality for the pandemic period (3/12/2020-12/31/2020)^*</td>
<td>49.1 (45.3, 52.8)</td>
<td>&lt;.001</td>
<td>33.4 (25.9, 40.9)</td>
<td>&lt;.001</td>
<td>-5.0 (-2.5, 14.9)</td>
</tr>
</tbody>
</table>

---

Residents were enrolled in Medicare Fee-for-Service during the entire year prior. Residents lived in assisted living on January 1, 2019, or January 1, 2020. We define memory care as AL communities with a state license, designation, or certification specific to dementia care. Data came from the 2018 and 2019 Medicare Master Beneficiary Summary file and chronic conditions.

*As of December 31, the year prior.

^1Of the conditions listed above.

We assigned the week beginning March 12, 2020, as the first week of the pandemic because COVID-19 was declared a national emergency on March 13, 2020.12 Rates were adjusted for age, race, sex, dual eligibility, the presence and number of chronic conditions, AL community size, and county fixed effects.
rates of excess all-cause mortality during the COVID-19 pandemic than residents without ADRD.\textsuperscript{1,2} This difference was robust to adjustment for other risk factors for mortality that are common among individuals with ADRD such as advanced age and chronic conditions. Although additional research is needed to explore mechanisms for this finding, it could be posited that individuals with ADRD may have more exposure to the virus because they are less likely to be able to follow social distancing guidelines or to wear a face covering; they also require more hands-on assistance from staff.\textsuperscript{2,19} Also, individuals with ADRD are less able to verbally express their symptoms, likely leading to delayed detection of COVID-19.\textsuperscript{20} Further, residents with ADRD are at risk of dysphasia, which heightens the likelihood of aspiration and thus pneumonia\textsuperscript{\textsuperscript{2}}; in addition, pneumonia complicates the course of COVID-19, increasing the risk of mortality.\textsuperscript{2} As another potential risk factor—and although the US Food and Drug Administration discourages the practice—long-term care residents with ADRD

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig1.png}
\caption{The unadjusted weekly rate of excess all-cause mortality per 100,000 assisted living residents during COVID-19 comparing assisted living residents with diagnoses of ADRD to those without ADRD. Weekly unadjusted excess all-cause mortality was calculated using the Centers for Medicare & Medicaid Services Vital Status file. The calendar week began on January 1 of each year. Assisted living residents with Medicare Advantage and residents in small assisted living communities (\textlt;25 beds) were excluded. Minnesota and Connecticut were excluded because of their different licensing structures. Shaded areas represent CIs.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig2.png}
\caption{The unadjusted weekly rate of excess mortality per 100,000 assisted living residents during COVID-19 comparing assisted living residents with ADRD in memory care and general assisted living communities. Weekly unadjusted excess all-cause mortality was calculated using the Centers for Medicare & Medicaid Services Vital Status file. The calendar week began on January 1 of each year. Assisted living residents with Medicare Advantage and residents in small assisted living communities (\textlt;25 beds) were excluded. The subsample includes 30 states in which we have information regarding whether they provide memory care. We define memory care as AL communities with a state license, designation, or certification specific to dementia care (Supplementary Table 1). Shaded areas represent CIs.}
\end{figure}
are often prescribed antipsychotics to manage behavioral expres-
sions.24 Taking antipsychotics is associated with increased risk of
thromboembolism among individuals with dementia, which may be
exacerbated by a COVID-19 infection.22,23
We did not find that memory care AL communities experienced
differential rates of excess all-cause mortality during COVID-19 when
compared to general AL communities, despite the fact that prior
research suggests residents in these communities have more
advanced dementia than residents in communities that do not provide
memory care.24 The fact that residents in memory care did not fare
worse (which could be expected given that residents who have more
advanced dementia are at higher risk for COVID-19 and COVID-
19–related mortality) suggests that memory care communities have
structures and processes of care that are advantageous in the context
of infection prevention such as more consistent staff assignment.24
Additionally, memory care communities often have higher staffing
levels,25 which may confer more risk, as having a higher number of
staff members is associated with increased risk of COVID-19.26 On
the other hand, more nurse staff hours is associated with decreased
COVID-19 mortality in nursing homes once 1 case of COVID-19 has
been detected.27 Of course, challenges faced during the pandemic
affected dementia care communities and general AL communities
alike, which may explain our null findings. Across both types, ad-
ministrators expressed difficulties maintaining staffing levels, man-
aging staff burnout, and keeping abreast of rapidly changing policy
decisions.28 and communities often did not have adequate personal
protective equipment, as nursing homes were the first to receive these
resources.29
Although the number of memory care AL communities has
increased in recent years, there is much we do not know about this
setting. A systematic review of studies about dementia care in nursing
facilities and residential care settings found very limited evidence that
these specialized settings improved resident outcomes,10 but they do
tend to relate to reduced nursing home admissions for residents with
dementia.11 Variation in how states regulate “memory care,” such as
requirements for staffing levels and building design features12 or
different licensing standards,30 likely contribute to the mixed study
findings. There is need for additional research to examine how states’
regulatory approaches and variable models of care relate to resident
health and well-being.

Limitations
Importantly, we identified AL communities providing memory care
as those with a state license, designation, or certification specific to
dementia care. In some states, this designation applies to only a unit or
a wing within an AL community, meaning that in such cases, we surely
identified some residents with ADRD who resided in a portion of the AL
community that was not licensed as memory care, but attributed them
to memory care because of this lack of differentiation; this under-
identification would again bias our findings toward the null. In addition,
administrative data are not collected for research purposes and the
validity of diagnostic codes to identify medical conditions is variable.31
Further, underdiagnosis of ADRD in the Medicare population, most
especially within the general AL population,28 suggests that there are
more residents with ADRD than reported, affecting the accuracy of the
estimates overall and perhaps the association with memory care.
Additional limitations are that we did not include individuals
residing in smaller (<25-bed) AL communities, and that because of
our reliance on Medicare claims for identifying dementia status and
comorbidities, we did not include AL residents who were enrolled in
Medicare Advantage. We also did not have information on memory
care licensure for 18 states; thus, caution should be used when
extrapolating results to residents in these states. In addition, although
we controlled for county fixed effects, there may have been additional
variation in COVID-19 prevalence at smaller geographies that could
have influenced our findings.

Conclusions and Implications
This study found that AL residents with ADRD were particularly
vulnerable to excess all-cause mortality during the COVID-19
pandemic, regardless of whether they resided in memory care or
general AL. Our findings illustrate the importance of infection pre-
vention and treatment strategies for residents with ADRD who reside in
AL communities. Memory care AL likely faced the same burdens
(lack of access to PPE, staffing shortage) as general AL, and the fact
that their residents did not fare worse—despite previous research sugges-
ting that they have more advanced dementia14—that suggests potential
benefits to infection control in these settings. More information is
needed about memory care AL, including whether and how they can
best protect vulnerable residents from infectious diseases as well as
other emergencies and disasters (eg, fires, climate change).

Acknowledgments
Wenhan Zhang, MPH (Brown University), helped create the cohort.

References
with coronavirus disease 2019: a systematic review and meta-analysis. Geriatr
2. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-
cause 30-day mortality in nursing home residents with COVID-19. JAMA
3. Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and miti-
gating the impact of the COVID-19 pandemic on Alzheimer’s disease and
include assisted living in responding to the COVID-19 pandemic. J Am Med Dir
of excess mortality rates among US assisted living residents during the COVID-
assisted living communities: Neighborhood deprivation and state social
sr03_43-508.pdf Google Scholar.
pertaining to infection control and pandemic response in US assisted living
missions among assisted-living residents with dementia. Alzheimers Dement.
12. Carder PC. State regulatory approaches for dementia care in residential care
13. Crouch M. Memory care: specialized support for people with Alzheimer’s or
basics/info-2019/memory-care-alzheimers-dementia.html
15. Thomas KS, Dosa D, Gozalo PL, et al. A methodology to identify a cohort of
Medicare beneficiaries residing in large assisted living facilities using admin-
update the list of underlying medical conditions that increase a person’s risk of
severe illness from COVID-19. Updated May 12, 2021. Accessed October 11,
lying-evidence-table.html
and after the US declaration of a national emergency concerning the COVID-19


Supplementary Fig. 1. Sample selection flowchart for the analysis comparing residents with ADRD to residents without ADRD. (ADRD, Alzheimer’s disease and related dementias.)
Supplementary Fig. 2. Sample selection flowchart for subanalysis comparing residents with ADRD in memory care to residents with ADRD in general AL. (ADRD, Alzheimer’s disease and related dementias; AL, assisted living.)
<table>
<thead>
<tr>
<th>States Where Memory Care Licensure Data Were Available in 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alabama</td>
</tr>
<tr>
<td>Florida</td>
</tr>
<tr>
<td>Illinois</td>
</tr>
<tr>
<td>Indiana</td>
</tr>
<tr>
<td>Maine</td>
</tr>
<tr>
<td>Nebraska</td>
</tr>
<tr>
<td>New Jersey</td>
</tr>
<tr>
<td>New York</td>
</tr>
<tr>
<td>Ohio</td>
</tr>
<tr>
<td>Oklahoma</td>
</tr>
<tr>
<td>Texas</td>
</tr>
<tr>
<td>Virginia</td>
</tr>
<tr>
<td>Washington</td>
</tr>
</tbody>
</table>
### Supplementary Table 2
The RECORD Statement—Checklist of Items, Extended From the STROBE Statement, That Should Be Reported in Observational Studies Using Routinely Collected Health Data

<table>
<thead>
<tr>
<th>STROBE Items</th>
<th>RECORD Items</th>
<th>Location in Manuscript where Items are Reported</th>
</tr>
</thead>
</table>
| (a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. | Abstract p. 1 (methods)  
Abstract p. 1 (setting and participants)  
Abstract p. 1 (methods) |
| Explain the scientific background and rationale for the investigation being reported | State specific objectives, including any prespecified hypotheses  
Present key elements of study design early in the paper  
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection (a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants.  
Describe methods of follow-up  
Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  
Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  
Case-control study - For matched studies, give matching criteria and the number of controls per case | Introduction pp. 3 and 4.  
Introduction p. 4.  
Introduction pp. 4 and 5  
Introduction pp. 4 and 5 |
| RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.  
RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  
RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  
RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided. | Supplementary Figure 1 (referenced on page 5);  
Brown Digital Repository (referenced on p. 7) | Brown Digital Repository (referenced on p. 7)  
Brown Digital Repository (referenced on p. 7)  
Supplementary Figure 1 (referenced on p. 5)  
Brown Digital Repository (referenced on p. 7) |

(continued on next page)
<table>
<thead>
<tr>
<th>STROBE Items</th>
<th>RECORD Items</th>
<th>Location in Manuscript where Items are Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Describe all statistical methods, including those used to control for confounding</td>
<td>RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.</td>
<td>Brown Digital Repository (referenced on p. 7)</td>
</tr>
<tr>
<td>(b) Describe any methods used to examine subgroups and interactions</td>
<td>RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.</td>
<td>Brown Digital Repository (referenced on p. 7)</td>
</tr>
<tr>
<td>(c) Explain how missing data were addressed</td>
<td>RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across 2 or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.</td>
<td>Supplementary Figure 1 (referenced on page 5)</td>
</tr>
<tr>
<td>(d) Cohort study - If applicable, explain how loss to follow-up was addressed</td>
<td>RECORD 13.1: Describe in detail the selection of the persons included in the study (i.e., study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.</td>
<td>Tables 1 and 2</td>
</tr>
<tr>
<td>Case-control study - If applicable, explain how matching of cases and controls was addressed</td>
<td></td>
<td>Figures 1 and 2</td>
</tr>
<tr>
<td>Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy</td>
<td></td>
<td>Figures 1 and 2, Table 3</td>
</tr>
<tr>
<td>(e) Describe any sensitivity analyses</td>
<td></td>
<td>Table 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pp. 9 and 10</td>
</tr>
</tbody>
</table>

---

**Supplementary Table 2 (continued)**

<table>
<thead>
<tr>
<th>STROBE Items</th>
<th>RECORD Items</th>
<th>Location in Manuscript where Items are Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) Give reasons for non-participation at each stage.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(c) Consider use of a flow diagram</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) Indicate the number of participants with missing data for each variable of interest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(c) Cohort study - summarise follow-up time (e.g., average and total amount)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort study - Report numbers of outcome events or summary measures over time</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case-control study - Report numbers in each exposure category, or summary measures of exposure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cross-sectional study - Report numbers of outcome events or summary measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) Report category boundaries when continuous variables were categorized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summarise key results with reference to study objectives</td>
<td></td>
<td>pp. 9 and 10</td>
</tr>
</tbody>
</table>
Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.

Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.

Discuss the generalisability (external validity) of the study results.

Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.

---

**RECORD 19.1:** Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.

**p. 11**

**RECORD 22.1:** Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.

**Brown Digital Repository (referenced on p. 7)**

---